Supplement Articles

Epigenetic Agents for the Treatment of Hematologic Malignancies 1/20/2011

Four epigenetic agents (vorinostat, romidepsin, azacitidine, decitabine) have been approved by the FDA for the treatment of hematologic malignancies.

Typical Drug Interactions in Oncology 1/20/2011

Precise data are not available, but the occurrence of drug-drug interactions in oncology is theorized to be higher than in most other conditions.